The creation of each new biotechnology enables a tool, a therapy, or a diagnostic: a molecule, a protein, an app, a platform. And the process underneath isn’t just complex in the science and engineering of it, but in the go to market.
So who are the stakeholders in this process? In this podcast (which was originally recorded as a video), a16z bio fund general partners Jorge Conde and Vijay Pande give a quick hallway-conversation style overview on the stakeholders — as well as what the process is from inception to approval to market; how do go-to-market models differ; and what should founders know at the beginning of each path.
Jorge Conde is a general partner on the Bio + Health team at Andreessen Horowitz, focused on therapeutics, diagnostics, life sciences tools, and software.
Vijay Pande is the founding general partner of the Bio + Health team at Andreessen Horowitz, focused on the cross-section of biology and computer science.
The a16z Podcast discusses the most important ideas within technology with the people building it. Each episode aims to put listeners ahead of the curve, covering topics like AI, energy, genomics, space, and more.